Verizon Communications

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.

Baxalta is a biopharmaceutical company based in Cambridge, MA, specializing in the development and commercialization of innovative therapies for patients with rare diseases. With a focus on cutting-edge research and collaboration with healthcare providers, Baxalta aims to address unmet medical needs and improve the lives of those affected by rare conditions. Generated from their business information